Staff Reports
This week the House Select Committee on the Chinese Communist Party put America’s drug giants on notice. Representative John Moolenaar, the committee chair, sent formal information‑request letters to Merck, AbbVie, Pfizer, Eli Lilly and Bristol Myers Squibb demanding detailed records about clinical trials run in China — especially trials at People’s Liberation Army hospitals and sites in Xinjiang. This is not a friendly handshake. It’s a national security check‑up, and the clock the committee set is ticking.
What the committee asked for — and why it matters
The committee wants companies to hand over policies, due‑diligence files, clinical trial logs and data‑protection plans. It flagged that Merck alone is linked to over 200 studies in China and AbbVie to more than 100, with dozens in Xinjiang and at PLA medical centers. The Select Committee says trials at military hospitals could expose American biotech intellectual property to transfer — in short, America’s scientific edge could be quietly handed to a strategic rival. That is a clear national security concern, and a short response deadline shows the committee means business.
Ethics and security — two problems in one
There are two separate but related problems here. First: informed consent. Xinjiang is a region where credible human‑rights reports document forced labor and coercion. Asking whether trial participants there are truly volunteering is not paranoia; it’s a moral obligation. Second: sensitive data. Clinical trials aren’t just tests on patients — they generate know‑how, protocols and data that, in the wrong hands, accelerate someone else’s military medicine. Letting trials run in PLA hospitals is like giving your homework to the kid who copies it and then joins the debate team of your competitor.
Pharma’s choices: speed and profits or prudence and patriotism?
Drug companies will say they follow global ethics and that patient safety is their priority. Fair enough — but when rapid enrollment and cost savings are paired with risky locations, corporate boards need to show more backbone. Chasing fast trials in China because it’s cheaper and quicker looks a lot like putting profits over protection. CEOs such as Robert M. Davis at Merck, Robert A. Michael at AbbVie and Albert Bourla at Pfizer must answer clearly: did you vet the sites? Did you demand assurances of free consent? Did you encrypt and lock down trial data? If they can’t answer confidently, Congress should act where companies failed.
What should happen next
The committee should get the documents it asked for. If answers are dodged, subpoenas and public hearings should follow. Regulators must consider tougher rules on accepting foreign trial data — especially from PLA hospitals or Xinjiang — and Congress should finish the job on legislation that protects biotech IP and prevents offshoring of critical research. This isn’t anti‑business theater; it’s common sense. We can grow medicine and protect the nation at the same time. If drugmakers wanted to keep this quiet, they chose the wrong quiet: America’s security isn’t for sale to the highest bidder.
